U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 68 results

Status:
US Approved Rx (2014)
First approved in 2014

Class (Stereo):
CHEMICAL (ABSOLUTE)



Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R. It has been approved for the treatment of insomnia. The mechanism by which suvorexant exerts its therapeutic effect in insomnia is presumed to be through antagonism of orexi...
Status:
US Approved Rx (2022)
First approved in 2014

Class (Stereo):
CHEMICAL (ABSOLUTE)



Tasimelteon, developed by Vanda Pharmaceuticals Inc under license from Bristol-Myers Squibb Co, is a melatonin receptor agonist. Tasimelteon differs structurally from melatonin and drugs with known melatonin agonist activity, in particular by its dis...
Status:
US Approved Rx (2020)
First approved in 2005

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Ramelteon was approved by the United States (U.S.) in July 2005, and the Japanese Ministry of Health, Labour and Welfare in April 2010. It is currently available in the USA and Japan as ROZEREM and is indicated for the treatment of insomnia character...
Status:
US Approved Rx (2014)
First approved in 2004

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Eszopiclone is a nonbenzodiazepine hypnotic, pyrrolopyrazine derivative of the cyclopyrrolone class and is indicated for the short-term treatment of insomnia. While Eszopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepine...
Status:
US Approved Rx (2018)
First approved in 1999

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Dexmedetomide (biologically active dextroisomer of medetomidine) is an alpha2-adrenergic agonist which was approved by FDA for the sedation purposes. Upon administration the drug activates the alpha2 receptors thus inhibiting the release of norepinep...
Status:
US Approved Rx (2008)
First approved in 1999

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Zaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zaleplon is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other dr...
Status:
US Approved Rx (2012)
First approved in 1992

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Zolpidem is usually used for the treatment of insomnia as a hypnotic drug. It was also suggested to be effective in the treatment of dystonia in some studies. Zolpidem can be one of useful alternative pharmacological treatments for blepharospasm. Zol...
Status:
US Approved Rx (1997)
First approved in 1990

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Estazolam, a triazolobenzodiazepine derivative, is an oral hypnotic agent with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. Benzodiazepines bind nonspecifical...
Status:
US Approved Rx (2019)
First approved in 1985

Class (Stereo):
CHEMICAL (ACHIRAL)



Midazolam, previously marketed under the trade name Versed, is a medication used for anesthesia, procedural sedation, trouble sleeping, and severe agitation. Midazolam is a short-acting benzodiazepine central nervous system (CNS) depressant. Pharmaco...
Status:
US Approved Rx (1985)
First approved in 1985

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Quazepam is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Quazepam interact preferentially with the benzodiazepine-1 (BZ1) receptors. Most common...